as a result of altered aminoglycoside pharmacokinetics , morbidly obese patients required significantly larger mean doses ( 540 mg/d for gentamicin , 690 mg/d for tobramycin and 1970 mg/d for amikacin ) when compared to the normal weight patients ( 380 mg/d , 420 mg/d and 1420 mg/d , respectively ; p less than 0.005 ) in order to achieve comparable serum concentrations .
C0002556
aminoglycoside
C0002499
amikacin